$BOLD

CRANDELL KEITH sold $40K of BOLD (indirect holdings)

CRANDELL KEITH sold 16,000 indirectly-held shares of Boundless Bio, Inc. (BOLD) at $2.49 on 2026-07-01.

Original reporting
SEC EDGAR · CRANDELL KEITH
Published Jul 6, 2026, 9:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 6, 2026, 9:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BOLD
Neutral
medium confidence
Mentioned
$BOLD
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BOLDNeutralLow
01

Why it matters

The newest fact is the sale details (16,000 shares at $2.49; holdings after transaction: 0 shares) without any accompanying company-specific news.

02

Market read

Traders may monitor for follow-on insider activity, but this filing alone does not change fundamentals.

03

What to watch

The filing notes an indirect holding and that no 10b5-1 plan was used, but it does not explain the reason for sale or any concurrent company developments.

Relevance 3/10Novelty 4/10Timing: new Form 4 filed 2026-07-06 after-hours

Background

The article is a SEC Form 4 insider transaction disclosure for Boundless Bio, Inc.

Company-level read

Ticker impact

$BOLDNeutralMedium confidence
Context

Boundless Bio’s 10% owner CRANDELL KEITH sold 16,000 shares in an open-market transaction at $2.49 on 2026-07-01.

Expected impact

Likely limited near-term impact; any effect should be small and sentiment-driven.

Evidence & confidence

The filing discloses transaction size, price, and post-sale holdings (0 shares) but provides no operational, financial, or regulatory catalyst.

Market effects

No clear sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider sales can be non-informational (tax/liquidity) and the disclosed price/size may not signal a change in outlook.

Key entities

  • Boundless Bio, Inc.

    Subject of the Form 4 insider sale disclosure.

  • CRANDELL KEITH

    10% owner who sold 16,000 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LYCAMedAI 8/10

Venrock Healthcare Capital Partners III, L.P. (Koh Bong Y, Shah Nimish P) purchased $37.7M of LYCA (indirect holdings)

Venrock Healthcare Capital Partners III, L.P. purchased 2,045,440 indirectly-held shares of Lycia Therapeutics, Inc. (LYCA) at an average of $18.41 ($18.00–$26.97, $37.65M total) across 6 trades over 2026-10-23 to 2026-10-27. Filed jointly with VHCP Co-Investment Holdings III, LLC (10% owner), VHCP Management III, LLC (10% owner), Venrock Healthcare Capital Partners EG, L.P. (10% owner), VHCP Management EG, LLC (10% owner), Venrock Healthcare Capital Partners XP, L.P. (10% owner), VHCP Management XP, LLC (10% owner), Koh Bong Y (10% owner) and Shah Nimish P (10% owner).